OXFORD

Optimization of an Information Leaflet to Influence Medication Beliefs in Women With Breast Cancer: A Randomized Factorial Experiment

Sophie M.C. Green, MSc[1],* · **Louise H. Hall, PhD**[1], · **David P. French, PhD**[2], ·
Nikki Rousseau, PhD[3], · **Catherine Parbutt, MPharm**[4], · **Rebecca Walwyn, PhD**[3], ·
Samuel G. Smith, PhD[1], · **on behalf of the ROSETA investigators**

[1]Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
[2]Manchester Centre for Health Psychology, University of Manchester, Manchester, UK
[3]Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
[4]Medicines Management and Pharmacy Services, Leeds Teaching Hospitals NHS Trust Leeds, Leeds, UK

*Sophie Green
S.m.c.green@leeds.ac.uk

Abstract

Background Adherence to adjuvant endocrine therapy (AET) is low in women with breast cancer. Negative beliefs about the necessity of AET and high concerns are barriers to adherence.

Purpose To use the multiphase optimization strategy to optimize the content of an information leaflet intervention, to change AET beliefs.

Methods We conducted an online screening experiment using a 2^5 factorial design to optimize the leaflet. The leaflet had five components, each with two levels: (i) diagrams about AET mechanisms (on/off); (ii) infographics displaying AET benefits (enhanced/basic); (iii) AET side effects (enhanced/basic); (iv) answers to AET concerns (on/off); (v) breast cancer survivor (patient) input: quotes and photographs (on/off). Healthy adult women (*n* = 1,604), recruited via a market research company, were randomized to 1 of 32 experimental conditions, which determined the levels of components received. Participants completed the Beliefs about Medicines Questionnaire before and after viewing the leaflet.

Results There was a significant main effect of *patient input* on beliefs about medication (β = 0.063, *p* < .001). There was one significant synergistic two-way interaction between *diagrams* and *benefits* (β = 0.047, *p* = .006), and one antagonistic two-way interaction between *diagrams* and *side effects* (β = −0.029, *p* = .093). There was a synergistic three-way interaction between *diagrams, concerns,* and *patient input* (β = 0.029, *p* = .085), and an antagonistic four-way interaction between *diagrams, benefits, side effects,* and *concerns* (β = −0.038, *p* = .024). In a stepped approach, we screened in four components and screened out the side effects component.

Conclusions The optimized leaflet did not contain enhanced AET side effect information. Factorial experiments are efficient and effective for refining the content of information leaflet interventions.

Lay Summary

Adjuvant endocrine therapy (AET) is a medication given to women to stop breast cancer from returning. Many women do not take AET every day or stop taking it before they should. Some women do not take AET because they do not believe it will help them, or they have concerns about the side effects. We ran an online study aiming to create the best information leaflet to help women understand how AET is helpful and to reduce their concerns. The leaflet had five sections; diagrams explaining how AET works, visual pictures of the benefits of AET, information about the side effects, answers to common concerns, and quotes from other women with breast cancer. 1,604 healthy women filled in a questionnaire before and after looking at an information leaflet about AET. Women received different combinations of the five sections of the information leaflet. We found quotes from other women with breast cancer led to more positive beliefs about AET. Some sections of the leaflet worked better in combination, while other sections were worse in combination. Our results led us to remove the detailed side effect information from the leaflet, as in combination with the other sections this negatively affected women's beliefs about AET.

Keywords Breast cancer · Medication beliefs · Optimization · Factorial · Information leaflet

Introduction

Breast cancer is the most common cause of cancer death in women worldwide [1]. Adjuvant endocrine therapy (AET) is prescribed to women with estrogen receptor-positive (ER+) breast cancer for 5–10 years to prevent recurrence and mortality [2–4]. However, many women do not take AET as prescribed [5–7]. Nonadherence to AET increases the risk of recurrence and reduces survival and quality-adjusted life years [8, 9].

Medication beliefs, in the form of low perceived personal need for AET and high concerns about AET (e.g., burden

of side effects), are associated with lower AET adherence [6, 10–16]. The Necessity-Concerns Framework (NCF) suggests women weigh up their personal perceived need for AET, against their concerns in a cost-benefit analysis to decide whether to take AET [17].

An extended version of the self-regulation model of illness suggests illness representations could influence key medication beliefs regarding the necessity or concerns of medication [17, 18]. For example, stronger beliefs that AET can reduce the risk of recurrence (treatment control) have been associated with increased necessity beliefs, and reduced concerns [19]. Similarly, better understanding of how AET works (coherence) has been associated with fewer AET concerns, while attributing more physiological sensations (identity) to AET (e.g., side effects) has been associated with increased AET concerns [19]. It has been hypothesized that necessity and concern beliefs mediate the relationship between illness perceptions (e.g., treatment control, coherence) and medication adherence [18–20]. Therefore, illness representations may be potential intervention targets, which could consequently influence necessity and concern beliefs.

There is little understanding regarding effective strategies to target medication beliefs [21–23]. A randomized controlled trial (RCT) found small to moderate effect sizes on medication beliefs using a three-session cognitive behavioral approach [24]. RCTs involving single intervention and control arms can tell us whether the intervention package as a whole is more effective than a comparator, but they do not provide information on which components are affecting the outcome, or whether any components are interacting. This limits our understanding of how we can effectively target medication beliefs.

Medication beliefs are complex, and therefore a multicomponent intervention may be needed to target all aspects of the construct. The multiphase optimization strategy (MOST) is a framework used to optimize multicomponent interventions [25, 26]. MOST consists of three phases. The first and final phases reflect a classical approach in which an intervention package is prepared, and then evaluated, typically with a parallel groups RCT. MOST advocates for an additional optimization phase between the preparation and evaluation phases. In this optimization phase, highly efficient, fully powered experimental designs are used to estimate the main and interaction effects of intervention components [27]. Optimization trials allow intervention developers to screen out components having a negative or null effect on an outcome, or that are not justified based on resource demands. This has the potential to create more effective, affordable, scalable, and efficient intervention packages [28].

We aimed to prepare and optimize an information leaflet intervention, aiming to increase necessity beliefs and reduce concerns about AET. We had three objectives: (i) to evaluate the main effects of each component of the information leaflet on beliefs about AET, (ii) to estimate interactions between components of the information leaflet on beliefs about AET, and (iii) to establish an optimal combination of information leaflet components with regard to changing beliefs about AET.

Methods

Preparation Phase: Information Leaflet Intervention Development

As part of a wider program of research, we used intervention mapping combined with MOST to develop a written information leaflet to change AET medication beliefs [29]. A written information leaflet was chosen, as it is a low cost, implementable method that can provide accurate information about the benefits and risks of AET, which could encourage more balanced medication beliefs [30–35]. We chose five distinct intervention targets, based on the NCF, self-regulation model, causal learning theory, and existing literature [17, 18, 36]. Our conceptual model details how we hypothesized each component to influence medication beliefs (Fig. 1). The content of the leaflet


Fig. 1. Conceptual model

was developed with our patient group, consisting of five breast cancer survivors with experience taking AET, and a consultant pharmacist with clinical experience of AET. A professional design company designed the leaflet.

Optimization Phase: Randomized Factorial Screening Experiment

Experimental design

We conducted an online, 2^5 ($2 \times 2 \times 2 \times 2 \times 2$) factorial experiment. The primary outcome was participant's beliefs about AET. Five candidate components were used as factors with two levels (on vs. off, or enhanced vs. basic). We randomized participants to 1 of 32 experimental conditions, which determined which levels of the components of the information leaflet participants would view (Table 1). Participants could receive any combination of the five components. One author (S.G.) created information leaflet versions corresponding to the experimental condition. A

second author (S.S.) reviewed 20% (6 information leaflets) of the intervention information leaflets to check the correct levels of each candidate component were included. The reading level for the 32 versions of the information leaflet ranged from 6.8 to 7.6 on the Flesch–Kincaid reading grade level; between "easy to read" and "fairly easy to read," respectively [37].

Participants answered demographic questions followed by a scenario asking them to imagine they had been diagnosed with breast cancer and had been prescribed AET (Supplementary Material 1). This scenario aimed to reflect the information received when women are prescribed AET, and received patient input. Participants could not proceed until 30 s had passed to encourage them to read the scenario. Participants then completed a questionnaire regarding their beliefs about AET, before being randomized to 1 of 32 experimental conditions. The relevant information leaflet was displayed, and they could not proceed until 3 min had passed. Following this, participants were asked to complete the same

Table 1. Experimental conditions in 2^5 factorial design and number randomized to each condition

	Constant Component	Diagrams	Benefits	Side effects	Common concerns	Patient input	Number randomized
1	Yes	Yes	Enhanced	Enhanced	Yes	Yes	55
2	Yes	Yes	Enhanced	Enhanced	Yes	No	54
3	Yes	Yes	Enhanced	Enhanced	No	Yes	53
4	Yes	Yes	Enhanced	Enhanced	No	No	38
5	Yes	Yes	Enhanced	Basic	Yes	Yes	53
6	Yes	Yes	Enhanced	Basic	Yes	No	56
7	Yes	Yes	Enhanced	Basic	No	Yes	47
8	Yes	Yes	Enhanced	Basic	No	No	58
9	Yes	Yes	Basic	Enhanced	Yes	Yes	45
10	Yes	Yes	Basic	Enhanced	Yes	No	57
11	Yes	Yes	Basic	Enhanced	No	Yes	42
12	Yes	Yes	Basic	Enhanced	No	No	50
13	Yes	Yes	Basic	Basic	Yes	Yes	54
14	Yes	Yes	Basic	Basic	Yes	No	41
15	Yes	Yes	Basic	Basic	No	Yes	49
16	Yes	Yes	Basic	Basic	No	No	63
17	Yes	No	Enhanced	Enhanced	Yes	Yes	45
18	Yes	No	Enhanced	Enhanced	Yes	No	55
19	Yes	No	Enhanced	Enhanced	No	Yes	56
20	Yes	No	Enhanced	Enhanced	No	No	42
21	Yes	No	Enhanced	Basic	Yes	Yes	61
22	Yes	No	Enhanced	Basic	Yes	No	52
23	Yes	No	Enhanced	Basic	No	Yes	54
24	Yes	No	Enhanced	Basic	No	No	58
25	Yes	No	Basic	Enhanced	Yes	Yes	44
26	Yes	No	Basic	Enhanced	Yes	No	51
27	Yes	No	Basic	Enhanced	No	Yes	40
28	Yes	No	Basic	Enhanced	No	No	50
29	Yes	No	Basic	Basic	Yes	Yes	46
30	Yes	No	Basic	Basic	Yes	No	39
31	Yes	No	Basic	Basic	No	Yes	43
32	Yes	No	Basic	Basic	No	No	52

Each component had two levels: on vs. off, or enhanced vs. basic.

questionnaire about their beliefs about AET. Data were collected in May 2022.

Participants and setting

A market research company sent out the survey link to their panel of profiled respondents in the UK who have signed up to participate in market research. Participants confirmed they were female, over 18 and could read English. The market research company provided participants with a small incentive. The experiment took place online. We used a sample of healthy women as a pragmatic decision based on recruitment costs. This reflects the resource management principle in the MOST framework, which emphasizes the importance of making the best use of available resources through balancing cost and scientific yield [38].

Candidate intervention components

Constant component

This information was not empirically examined, as all participants received this component. It consisted of a title page, a description of the types of AET, an explanation about how AET works, and how to take AET.

Diagrams detailing the mechanisms of AET (diagrams)

Better understanding of how AET works has been associated with fewer concerns about AET [19]. Visual information, in the form of medical diagrams, may aid understanding as to how a medication works and can be easier to remember [39–41]. This component consisted of two levels; on, in which medical diagrams supplemented text explaining how AET works, and off, in which text alone explained the mechanisms of AET.

Information about the benefits of AET (benefits)

Beliefs about treatment control have correlated negatively with medication concerns, and positively with necessity beliefs [19]. Visual aids, such as icon arrays, can help readers understand information, and are helpful for those with low numeracy [42]. In the enhanced level, information was provided regarding the benefits of AET, with two icon arrays to support this. In the basic level, one statement acknowledged that AET reduced the risk of recurrence and mortality.

Information about the prevalence of side effects (side effects)

Misattributing symptoms to AET contributes to the nocebo effect, which can influence the formation of medication beliefs [31, 43–45]. Displaying frequencies of side effects using numerical values, positively framing side effect information (e.g., 99% of people will not experience this side effect), and informing people about the nocebo effect could lead to reduced attribution of symptoms to a medication [43, 46–48]. The enhanced level details the prevalence of side effects of AET, using positive framing. Additional text challenges attribution of side effects to the medication. The basic level includes a side effect table indicating which side effects are possible, but no information about their prevalence or attribution.

Answers to common concerns about AET (concerns)

Negative expectations about a medication contribute to the nocebo effect, and have been associated with increased side effect reporting in women taking AET [32, 44, 45]. Addressing common concerns could reduce negative expectations of AET. This component is made up of answers to four common concerns informed by existing qualitative studies and suggestions from our patient group [14–16]. For example, worry about not being able to cope with side effects was addressed by suggesting that for many women side effects are manageable, but that further support can be sought if they are disruptive. This component was either present or absent.

Input from breast cancer survivors (patient input)

Narrative information, such as patient stories, can increase engagement with educational materials [49]. This component comprises four quotes, photos from women with experience taking AET, and a statement highlighting the leaflet has been codesigned. This component was present or absent.

Measures

Participant characteristics

Information was collected regarding participant's age, marital status, education level, ethnicity, menopausal status, and previous breast cancer diagnoses. If participants reported a breast cancer diagnosis, they were asked the stage and whether they had ever taken AET. All participants were additionally asked whether any close relations had been diagnosed with breast cancer.

Beliefs about Medication Questionnaire-AET (BMQ-AET)

The 10-item BMQ-AET was used to assess specific medication beliefs [50]. Participants responded on a 5-point scale ranging from "strongly disagree" to "strongly agree." The BMQ-AET consists of two subscales; specific concerns and necessity beliefs, with five items relating to each subscale. As suggested by the authors of the original BMQ [17], and to reflect the need for a singular outcome capturing both necessity beliefs and concerns for a factorial experiment, we decided a priori to calculate a BMQ-AET differential score. This was calculated by subtracting concern from necessity scores (range –20 to +20).

Statistical considerations

Sample size

Sample size was calculated using the "MOST" package in R Studio [51]. To detect an effect size of 0.15, with 0.9 power and alpha set to 0.1, a sample size of 1,524 was required. It was assumed that 5% of participants would enter "nonsense" responses (defined as completing the survey in less than a third of the median time taken to complete the survey). Therefore, the sample size was increased to 1,604. The effect size chosen was based on the minimum effect of interest. Alpha was set to 0.1 rather than the traditional 0.05. This is due to the aim of this study being to screen components; incorrectly screening out and incorrectly screening in a component (the result of Type I and II error rates) are equally detrimental. This reflects the decision priority perspective taken in the optimization phase of MOST [52].

Randomization

Simple randomization was used in which each participant was randomly assigned to one of 32 experimental conditions [53]. The randomization was conducted automatically in the online survey platform, Qualtrics.

Table 2. Demographics of participants

Demographics	Total sample (N = 1,603)
Age, mean (SD, range)	47.93 (16.29; 18–83)
Marital status (%)	
Single	398 (24.8)
Married	749 (46.7)
Cohabiting/ living with a partner	244 (15.2)
Divorced/ separated	159 (9.9)
Widowed	53 (3.3)
Education (%)	
GCSE/O-Level/CSE	374 (23.3)
Vocational qualifications (NVQ1 + 2)	142 (8.9)
A-Level	269 (16.8)
Higher educational qualifications (below degree)	190 (11.9)
Degree-level education	547 (34.1)
Still studying	9 (0.6)
Other	18 (1.1)
No formal qualifications	54 (3.4)
Ethnicity (%)	
Asian or Asian British	78 (4.9)
Black or Black British (African)	16 (1.0)
Black or Black British (Caribbean)	10 (0.6)
Mixed	27 (1.7)
Chinese	6 (0.4)
White British	1,424 (88.8)
Other	36 (2.3)
Do not wish to answer	6 (0.4)
Menopausal status (%)	
Premenopausal	697 (43.5)
Postmenopausal	684 (42.7)
Unsure	222 (13.9)
Previous breast cancer diagnosis (%)	79 (4.9)
Stage of breast cancer (%)[a]	
Stage 0	3 (3.8)
Stage 1	25 (31.7)
Stage 2	22 (27.8)
Stage 3	11 (13.9)
Stage 4	1 (1.3)
Unsure	17 (21.5)
ER+ Breast cancer (%)[a]	
Yes	67 (84.8)
No	12 (15.2)
Experience with AET[a]	
Currently taking	35 (44.3)
Previously taken	23 (29.1)
No experience	15 (19.0)
Unsure	6 (7.6)
Type of hormone therapy[a]	
Tamoxifen	29 (36.7)
Anastrozole	22 (27.8)
Letrozole	17 (21.5)
Exemestane	3 (3.8)
Other	1 (1.3)

Table 2. Continued

Demographics	Total sample (N = 1,603)
Close relations experience of breast cancer	732 (45.7)
Parent	167 (10.4)
Sibling	72 (4.5)
Grandparent	114 (7.1)
Partner	15 (0.9)
Close friend	311 (19.4)
Other	143 (8.9)

[a]Percentages calculated only from those who have had breast cancer (n = 79).

Missing data

Data for participants who did not complete the survey was not recorded. All fields in the survey were mandatory and therefore there was no missing data.

Statistical analysis

Primary analyses

The primary outcome was the BMQ-AET differential score after viewing the information leaflet. Descriptive statistics were used to summarize necessity belief, concern, and BMQ-AET differential scores overall and by component. Multiple linear regression with effect coding (−1, +1) was used to directly assess the main effects and the interaction effects of the components on the BMQ-AET differential. The model included all main effects and all interactions, and baseline BMQ-AET differential scores and age as covariates. Coefficients are reported as they originate from the model, which is half what they would traditionally be defined to be, due to the use of effect coding. Data were analyzed using R Statistical Software (R version 4.2.0, April 22, 2022) [54] on an intent-to-treat basis (R packages detailed in Supplementary Material 2).

Sensitivity analyses

We repeated the primary analysis removing speed responders, defined as anyone who fit one of three criteria: (i) completed the whole survey in less than a third of the median time it took participants to complete the survey, (ii) answered the same response to all items in the BMQ-AET pretest, and (iii) answered the same response to all items in the BMQ-AET posttest. Our second sensitivity analysis removed participants who reported a diagnosis of breast cancer, to assess if decisions would change without this group. Sensitivity analysis was not conducted for only participants reporting a breast cancer diagnosis due to the low number of participants (n = 79).

Screening decisions

A decision priority perspective was taken to select components to include in the optimized information leaflet [52]. The all-active components criterion was used to make screening decisions, which is defined as the best expected outcome irrespective of cost or other constraints [52]. The criteria for a component to be considered for inclusion in the optimized package was set a priori at $p < .1$ for main effects and interaction effects. Any main effects and interaction effects which were considered important (i.e., $p < .1$) were added into the parsimonious prediction model. Coefficients for all other effects not considered important (i.e., $p > .1$) were set to zero.

Table 3. Descriptives for baseline and follow-up beliefs about medicines scale scores (*n* = 1,603)

Factor level	Baseline, mean (SD)			Follow-up, mean (SD)		
	Necessity[a]	Concerns[a]	Differential[b]	Necessity[a]	Concerns[a]	Differential[b]
Total	17.99 (4.28)	16.47 (3.97)	1.52 (5.36)	18.73 (4.20)	16.43 (4.11)	2.31 (5.72)
Diagrams						
On	17.98 (4.36)	16.44 (4.03)	1.54 (5.46)	18.80 (4.27)	16.42 (4.16)	2.37 (5.93)
Off	18.00 (4.19)	16.50 (3.90)	1.50 (5.25)	18.67 (4.14)	16.43 (4.06)	2.24 (5.49)
Benefits						
On	17.99 (4.37)	16.60 (3.93)	1.39 (5.21)	18.70 (4.16)	16.54 (4.05)	2.16 (5.60)
Off	17.99 (4.18)	16.33 (4.00)	1.67 (5.52)	18.78 (4.25)	16.31 (4.17)	2.47 (5.84)
Side effects						
On	17.94 (4.31)	16.55 (3.94)	1.39 (5.25)	18.75 (4.21)	16.53 (4.00)	2.22 (5.51)
Off	18.04 (4.25)	16.39 (4.00)	1.64 (5.46)	18.71 (4.20)	16.33 (4.21)	2.38 (5.91)
Concerns						
On	17.88 (4.38)	16.34 (4.01)	1.54 (5.23)	18.60 (4.26)	16.27 (4.10)	2.33 (5.47)
Off	18.10 (4.17)	16.60 (3.92)	1.50 (5.49)	18.87 (4.14)	16.59 (4.11)	2.28 (5.96)
Patient input						
On	18.09 (4.27)	16.51 (3.95)	1.59 (5.44)	18.94 (4.26)	16.22 (4.08)	2.72 (5.74)
Off	17.89 (4.28)	16.43 (3.98)	1.46 (5.29)	18.54 (4.14)	16.63 (4.13)	1.91 (5.67)

[a]Possible range: 5–25.
[b]Possible range: –20 to +20.

Decision-making followed a stepped approach [52]. Following the principle of "effect hierarchy," which suggests that main effects and lower-order interaction effects are the most scientifically important, main effects were considered initially to screen components in and out [55]. Decisions were reconsidered in light of interaction effects, prioritizing lower-order interactions and those containing a component where a main effect was present. After considering all interactions, any components on the screened-in list were set to the higher level, and any components on the screened-out list were set to the lower level to make up the optimized information leaflet.

Results

Participant Characteristics
A total of 1,604 participants were randomized and completed the survey. One participant was removed due to being under 18 years old (Condition 29), leaving a primary population of 1,603 participants (Table 2). Most women were White British (88.8%), either married or living with a partner (61.9%), and around a third (34.1%) reported degree-level education. Seventy-nine (4.9%) women had a diagnosis of breast cancer, with 67/79 (84.8%) being estrogen or progesterone receptor positive. Fifty-eight women were currently taking AET or had previously taken AET. Table 3 displays the mean beliefs about medicines scores overall and by factor.

Engagement
The median time to complete the survey was 9.45 min (range = 4.87–85.25 min). The median time spent looking at the information leaflet (including the compulsory 3 min) ranged from 3.10 min (range = 3.02–29.28 min) in Condition 16, to 3.58 min in Condition 12 (range = 3.02–37.67 min) (Supplementary Material 3).

Optimization Experiment
The number of participants randomized to each of the 32 conditions ranged from 38 to 63 (Table 1). One component, *patient input*, had a statistically significant positive main effect on beliefs about AET (β = 0.063, 90% CI 0.035, 0.091, *p* < .001) (Table 4). There was one significant synergistic two-way interaction: *diagrams × benefits* (β = 0.047, 90% CI 0.019, 0.075, *p* = .006), in which the effect of *diagrams* was greater when *benefits* was enhanced. There was an antagonistic two-way interaction: *diagrams × side effects* (β = –0.029, 90% CI –0.056, –0.001, *p* = .093), in which the effect of *diagrams* was reduced when *side effects* was enhanced. There was a synergistic three-way interaction: *diagrams × concerns × patient input* (β = 0.029, 90% CI 0.001, 0.057, *p* = .085), in which the presence of all three components set to on/enhanced was greater than would be expected from each component alone. Finally, there was an antagonistic four-way interaction: *diagrams × benefits × side effects × concerns* (β = –0.038, 90% CI –0.066, –0.010, *p* = .024), in which *side effects* being enhanced reduced the effect of *diagrams, benefits, and concerns* (Figs. 2–5).

Based on this analysis, we constructed the parsimonious prediction model, containing only main effects and interactions meeting the threshold for importance (*p* < .1). Due to imbalance in the number of participants across conditions, the analysis was repeated including only the main effects and interactions of importance, and the covariates, baseline BMQ-AET and age [52]. There was minimal change in the coefficient values (Table 4).

Decision-making
Initially, the only component with an important main effect, *patient input*, was screened in. We then reconsidered the screened in and out lists based on the important interaction effects (*p* < .1). We examined the three-way *diagrams × concerns × patient input* interaction first, as this contained a component with a main effect (*patient input*). When *patient*

Table 4. Multiple linear regression showing the effect of candidate components on beliefs about AET

		Full regression model				Parsimonious prediction model			
		b-weight	β (90% CI)	t	p	b-weight	β (90% CI)	t	p
	Intercept	2.322		23.989	**<.001**	2.319		24.219	**<.001**
Main effects	Diagrams (D)	0.028	0.005 (−0.023, 0.033)	0.293	.770				
	Benefits (B)	−0.047	−0.008 (−0.036, 0.020)	−0.486	.627				
	Side effects (SE)	0.018	0.003 (−0.025, 0.031)	0.185	.853				
	Concerns (C)	−0.005	<0.001 (−0.029, 0.027)	−0.055	.956				
	Patient input (P)	0.362	0.063 (0.035, 0.091)	3.740	**<.001**	0.361	0.063 (0.036, 0.091)	3.773	**<.001**
Interactions	D × B	0.267	0.047 (0.019, 0.075)	2.757	**.006**	0.266	0.047 (0.019, 0.074)	2.770	**.006**
	D × SE	−0.163	−0.029 (−0.056, −0.001)	−1.683	**.093**	−0.163	−0.028 (−0.056, −0.001)	−1.693	.091
	B × SE	−0.102	−0.018 (−0.046, 0.010)	−1.051	.293				
	D × C	0.031	0.005 (−0.022, 0.033)	0.324	.746				
	B × C	−0.080	−0.014 (−0.042, 0.014)	−0.826	.409				
	SE × C	−0.072	−0.013 (−0.040, 0.015)	−0.745	.456				
	D × P	0.134	0.023 (−0.005, 0.051)	1.380	.168				
	B × P	0.002	<0.001 (−0.028, 0.028)	0.022	.983				
	SE × P	−0.121	−0.021 (−0.049, 0.007)	−1.253	.210				
	C × P	−0.035	−0.006 (−0.034, 0.022)	−0.357	.721				
	D × B × SE	−0.045	−0.008 (−0.036, 0.020)	−0.462	.644				
	D × B × C	−0.042	−0.007 (−0.035, 0.021)	−0.437	.663				
	D × SE × C	0.144	0.025 (−0.003, 0.053)	1.484	.138				
	B × SE × C	0.032	0.006 (−0.022, 0.033)	0.327	.744				
	D × B × P	0.086	0.015 (−0.013, 0.043)	0.888	.375				
	D × SE × P	0.130	0.023 (−0.005, 0.051)	1.344	.179				
	B × SE × P	0.061	0.011 (−0.017, 0.039)	0.632	.527				
	D × C × P	0.167	0.029 (0.001, 0.057)	1.726	**.085**	0.160	0.028 (0.000, 0.056)	1.664	.096
	B × C × P	0.047	0.008 (−0.020, 0.036)	0.481	.630				
	SE × C × P	−0.002	<0.001 (−0.028, 0.027)	−0.025	.980				
	D × B × SE × C	−0.219	−0.038 (−0.066, −0.010)	−2.261	**.024**	−0.224	−0.039 (−0.067, −0.012)	−2.332	**.020**
	D × B × SE × P	−0.096	−0.017 (−0.045, 0.011)	−0.987	.324				
	D × B × C × P	−0.157	−0.027 (−0.055, 0.001)	−1.614	.107				
	D × SE × C × P	0.070	0.012 (−0.016, 0.040)	0.724	.469				
	B × SE × C × P	0.107	0.019 (−0.009, 0.047)	1.105	.269				
	D × B × SE × C × P	0.095	0.017 (−0.011, 0.045)	0.980	.327				
Covariates	Baseline BMQ-AET	0.784	0.735 (0.707, 0.763)	42.842	**<.001**	0.785	0.736 (0.708, 0.764)	43.291	**<.001**
	Age	0.003	0.010 (−0.018, 0.038)	0.575	.566	0.005	0.014 (−0.014, 0.042)	0.846	.397

input was set to on, the effect of *concerns* was higher when *diagrams* was also set to on. Setting all three components to the higher levels had the optimum effect (Fig. 2). Therefore, *concerns* and *diagrams* were screened in.

Next, we examined the *diagrams × benefits* interaction (Fig. 3). There was a significant synergistic interaction in which the effect of *diagrams* was increased when *benefits* was set to on. The optimum effect occurred when either both components were set to the higher or lower level. As *diagrams* was screened in previously, it was more beneficial to screen in *benefits*, rather than screen out both *benefits* and *diagrams*.

The antagonistic *diagrams × side effects* interaction highlights the effect of *diagrams* was reduced when *side effects* was set to the higher level (Fig. 4). When both components were set to the higher level, the BMQ-AET differential was smaller than would be expected with no interaction. Therefore, *side effects* remained screened out.

Finally, we examined the four-way *diagrams × benefits × side effects × concerns* interaction (Fig. 5). Here we examined what effect *side effects* would have when all other components involved are set to the higher levels, as this reflected the screened-in and screened-out list at this stage. When *diagrams, benefits,* and *concerns* were set to their higher levels, *side effects* being set to the higher level diminished the effect. Therefore, *side effects* remained screened out, meaning the basic level of *side effects* was included in the optimized information leaflet.

Table 5 lists the predicted outcomes for $\hat{Y}_{\text{Beliefs}}$ for all 16 conditions reflecting all combinations of the four screened-in components, computed using the expression for the parsimonious prediction model. Condition 5 had the greatest $\hat{Y}_{\text{Beliefs}}$ value, which represents *diagrams, benefits, concerns,* and *patient input* being screened in, and *side effects* screened out.

**Fig. 2.** Three-way synergistic interaction between *patient input*, *diagrams*, and *concerns* components

**Fig. 3.** Two-way synergistic interaction between *benefits* and *diagrams* components

Fig. 4. Two-way antagonistic interaction between *diagrams* and *side effects* components

Sensitivity Analyses

When removing speed responders ($n = 153$), the results were consistent with the primary analysis (Supplementary Material 4). The only important effect to change was the three-way *diagrams × concerns × patient input* interaction which became nonsignificant ($p = .103$), but this did not impact which components were screened out. Demographic and clinical characteristics were comparable between women with and without breast cancer (Supplementary Material 4). There was no significant difference in baseline BMQ-AET differential scores between women with breast cancer ($M = 2.19$, $SD = 5.93$) and women without breast cancer ($M = 1.49$, $SD = 5.33$) $t(1,601) = 1.14$, $p = .259$. Women with breast cancer had significantly higher baseline necessity beliefs ($M = 18.92$, $SD = 4.27$) than those without breast cancer ($M = 17.94$, $SD = 4.27$), $t(1,601) = 1.99$, $p = .047$ (Supplementary Material 4). When removing participants reporting a diagnosis of breast cancer ($n = 79$), results were consistent with the primary analysis and decision-making did not change (Supplementary Material 4).

Discussion

Using an online factorial screening experiment, we optimized an information leaflet intervention to increase beliefs about the necessity of AET and reduce concerns about AET. The optimized information leaflet contained four out of five of the candidate components; diagrams explaining how AET works *(diagrams)*, icon arrays explaining the benefits of AET *(benefits)*, answers to common concerns about AET *(concerns)*, and quotes and photographs of breast cancer survivors explaining their motivations for taking AET *(patient input)*. The side effect component *(side effects)* was screened out due to interacting negatively with the other candidate components. The optimization process led to development of a more efficient and effective information leaflet.

We have demonstrated that it is feasible and beneficial to optimize an information leaflet using an online factorial experiment. Compared with a classical approach (i.e., using an RCT to evaluate the leaflet as a package), the optimization phase provided an insight into the contributions of individual components of the leaflet in isolation and combined. From this, we know that the leaflet supports medication beliefs, which is a known barrier to AET adherence [6, 10–16]. The resulting leaflet is optimized to increase efficiency (e.g., redundant components are not included) and effectiveness (e.g., only components reaching an a priori statistical significance are included).

The strategies we tested appear to be effective in changing medication beliefs, which builds on the limited existing evidence. These strategies could be applied in other contexts where medication beliefs are a barrier to adherence behaviors. However, our results suggest these strategies had more impact on increasing necessity beliefs than reducing concerns. While this was still effective in improving the cost-benefit analysis

Concerns = Off

Benefits = Basic

Benefits = Enhanced

Concerns = On

Benefits = Basic

Benefits = Enhanced

Fig. 5. Four-way antagonistic interaction between *benefits*, *diagrams*, *concerns*, and *side effects* components.

(differential) which has been found to be a more consistent predictor of nonadherence than necessity beliefs or concerns alone [56], future research could focus on developing components to better reduce concerns.

The *patient input* component was the only candidate component to demonstrate a main effect on beliefs about AET. In our conceptual model, we hypothesized that this component would interact with all other components, but it did not interact with the *side effects* and *benefits* components. The main effect suggests that the *patient input* component has an alternative mechanism for affecting beliefs about AET. One explanation is that the content of the quotes could have led to social comparison; in which participants may have adapted their beliefs after comparing with others, which is common in a state of uncertainty [57, 58]. Information about the main effects and interaction effects obtained in an optimization experiment enables refinement of our conceptual model and understanding of how interventions may work.

The only candidate component screened out of the optimized information leaflet was the *side effects* component. Informing participants of the nocebo effect (suggesting that not all physiological sensations may be caused by AET), and providing positively framed side effect information did not affect medication beliefs, and interacted negatively with the *diagrams, benefits* and *concerns* components. The lower level of this component could have provided the "gist" of the information sufficiently (i.e., the bottom line meaning that different side effects are possible for different types of AET). According to Fuzzy Trace Theory, health information may be encoded in two ways; a gist representation (the essence of the information), and a verbatim representation (literal, precise information, e.g., specific statistics) [59]. When making decisions, people tend to prefer to rely on the gist representation [59, 60]. In this case, the lower level of the *side effect* component may have been enough to form this gist-based representation, meaning the enhanced level of the component was redundant.

Table 5. Predicted beliefs about medications scores for each condition

Condition	Side effects	Diagrams	Benefits	Concerns	Patient input	$\hat{Y}_{Beliefs}$ [a]	$\hat{Y}_{Beliefs}$ [b]
5	**Basic**	**On**	**Enhanced**	**On**	**On**	**2.524**	**4.315**
6	Basic	On	Enhanced	On	Off	2.342	4.133
7	Basic	On	Enhanced	Off	On	2.390	4.181
8	Basic	On	Enhanced	Off	Off	2.320	4.111
13	Basic	On	Low	On	On	2.352	4.143
14	Basic	On	Low	On	Off	2.170	3.961
15	Basic	On	Low	Off	On	2.374	4.165
16	Basic	On	Low	Off	Off	2.304	4.095
21	Basic	Off	Enhanced	On	On	2.240	4.031
22	Basic	Off	Enhanced	On	Off	2.170	3.961
23	Basic	Off	Enhanced	Off	On	2.374	4.165
24	Basic	Off	Enhanced	Off	Off	2.192	3.983
29	Basic	Off	Low	On	On	2.412	4.203
30	Basic	Off	Low	On	Off	2.342	4.133
31	Basic	Off	Low	Off	On	2.390	4.181
32	Basic	Off	Low	Off	Off	2.208	3.999

[a]Predicted values calculated for the parsimonious model without covariates.
[b]Predicted values calculated for the parsimonious model with covariates.

Alternatively, participants may not have understood the enhanced side effect information, or a written intervention may not be sufficient to reduce concerns. Screening out the enhanced *side effect* component led to a more efficient information leaflet, with redundant information removed. Future work could explore alternative methods to reduce concerns further.

The synergistic interaction between the *diagrams* and *benefits* components was the only hypothesized interaction evident in our data. The lack of main effect but the presence of a synergistic interaction indicates these components only work together. Understanding how a medication works via the *diagrams* component may increase understanding and belief in the benefits of AET [61]. Therefore, it may be appropriate to combine these components into a single, more robust component [52].

Our study had limitations. Women with breast cancer reported significantly higher necessity beliefs at baseline than women without breast cancer (Supplementary Material 4), which could limit the generalizability of the findings to women with breast cancer. However, the concerns and differential scores were not significantly different between women with and without breast cancer at baseline or follow-up (Supplementary Material 4). BMQ-AET scores for the total sample and breast cancer subsample were comparable to previous published studies conducted with women with breast cancer [34, 62]. Further evaluation of the leaflet will be conducted in women with breast cancer. The majority of participants were White British and had higher level educational qualifications. A more diverse sample may have generated different findings that reflected a different optimal combination of components. As a result of using simple randomization, the number of participants in each experimental condition was not balanced which will have reduced statistical power. We optimized an information leaflet based on one singular outcome, but other outcomes could also be considered, such as women's satisfaction with the information they receive. Further work is needed to explore optimization with multiple

outcomes of interest. To limit the length of the survey, we did not include assessments of each component target (e.g., coherence). Future optimization studies could include these assessments to enable causal pathway analyses to enhance our understanding of the underlying mechanisms of action [63].

We used a rigorous approach to optimize an information leaflet to increase necessity beliefs and reduce concerns in women taking AET. Our approach has enabled refinement of our conceptual model, and has led to the development of a more efficient information leaflet, removing components that are negatively impacting the outcome. Factorial experimental designs offer a highly efficient way of optimizing multicomponent intervention packages such as information leaflets. Optimization, guided by MOST, can enhance our overall understanding of behavioral interventions.

Compliance with Ethical Standards

Authors' Statement of Conflict of Interest and Adherence to Ethical Standards Authors Sophie M.C. Green, Louise H. Hall, David P. French, Nikki Rousseau, Catherine Parbutt, Rebecca Walwyn, and Samuel G. Smith declare that they have no conflict of interest. All procedures, including the informed consent process, were conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.

Authors' Contributions Sophie Green, BSc, MSc (Conceptualization: Lead; Formal analysis: Lead; Funding acquisition: Supporting; Investigation: Lead; Methodology: Lead; Resources: Lead; Writing – original draft: Lead; Writing – review & editing: Lead), Louise H Hall, PhD (Methodology: Supporting; Resources: Supporting; Supervision: Equal; Writing – review & editing: Supporting), David P French, PhD (Methodology: Supporting; Resources: Supporting; Supervision: Equal; Writing – review & editing: Supporting), Nikki Rousseau, PhD (Methodology: Supporting; Resources: Supporting; Supervision: Equal; Writing – review & editing: Supporting), Catherine Parbutt, MPharm (Resources: Supporting; Writing – review & editing: Supporting), Rebecca Walwyn, PhD (Formal analysis: Supporting; Methodology: Supporting; Writing – review & editing: Supporting), and Samuel G Smith, PhD (Conceptualization: Supporting; Formal analysis: Supporting; Funding acquisition: Lead; Methodology: Supporting; Supervision: Equal; Writing – review & editing: Supporting)

Ethical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors.

Transparency Statement *Study Registration:* The study was not formally registered. *Analytic plan pre-registration:* The analysis plan was not formally pre-registered. *Data availability:* De-identified data associated with this paper are available from https://doi.org/10.5518/1302. *Analytic code availability:* Analytic code used to conduct the analyses presented in the current study is available from https://doi.org/10.5518/1302. *Materials availability:* Materials used to conduct the study may be available by emailing the corresponding author.

Supplementary Material

Supplementary material is available at *Annals of Behavioral Medicine* online.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018; 68(6):394–424.

2. Early Breast Cancer Trialists Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet.* 2011; 378(9793):771–784.

3. Early breast Cancer Trialists Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet.* 2015; 386(10001):1341–1352.

4. Gnant M, Fitzal F, Rinnerthaler G, et al.; Austrian Breast and Colorectal Cancer Study Group. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. *N Engl J Med.* 2021; 385(5):395–405.

5. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a Cohort of 8,769 early-stage breast cancer patients. *J Clin Oncol.* 2010; 28(27):4120–4128.

6. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Breast Cancer Res Treat.* 2012; 134(2):459–478.

7. Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. *Breast Cancer Res Treat.* 2013; 138(1):325–328.

8. McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. *Br J Cancer.* 2013; 109(5):1172–1180.

9. Inotai A, Ágh T, Maris R, et al. Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. *Cancer Treat Rev.* 2021; 100:102264.

10. Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. *Patient Prefer Adherence.* 2017; 11: 305–322.

11. Cahir C, Guinan E, Dombrowski SU, Sharp L, Bennett K. Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III breast cancer: a systematic review and meta-analysis. *Patient Educ Couns.* 2015; 98(12):1524–1539.

12. Brett J, Fenlon D, Boulton M, et al. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. *Eur J Cancer Care.* 2018; 27(1):e12601.

13. Toivonen K, Williamson T, Carlson L, Walker L, Campbell T. Potentially modifiable factors associated with adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review. *Cancers.* 2020; 13(1):107.

14. Brett J, Boulton M, Fenlon D, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. *Patient Prefer Adherence.* 2018; 12:291–300.

15. Moon Z, Moss-Morris R, Hunter MS, Hughes LD. Understanding tamoxifen adherence in women with breast cancer: a qualitative study. *Br J Health Psychol.* 2017; 22(4):978–997.

16. Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L. Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. *Support Care Cancer.* 2015; 23(11):3115–3130.

17. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *J Psychosom Res.* 1999; 47(6):555–567.

18. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment

beliefs in explaining non-adherence to preventer medication. *Psychol Health*. 2002; 17(1):17–32.

19. Moon Z, Moss-Morris R, Hunter MS, Hughes LD. Measuring illness representations in breast cancer survivors (BCS) prescribed tamoxifen: modification and validation of the Revised Illness Perceptions Questionnaire (IPQ-BCS). *Psychol Health*. 2017; 32(4):439–458.

20. Zhao M, Zhao J, Chen J, et al. The relationship between medication adherence and illness perception in breast cancer patients with adjuvant endocrine therapy: beliefs about medicines as mediators. *Support Care Cancer*. 2022; 30(12):10009–10017.

21. Hurtado-De-Mendoza A, Cabling ML, Lobo T, Dash C, Sheppard VB. Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review. *Clin Breast Cancer*. 2016; 16(4):247–255.e3.

22. Heiney SP, Parker PD, Felder TM, Adams SA, Omofuma OO, Hulett JM. A systematic review of interventions to improve adherence to endocrine therapy. *Breast Cancer Res Treat*. 2019; 173(3):499–510.

23. Finitsis DJ, Vose BA, Mahalak JG, Salner AL. Interventions to promote adherence to endocrine therapy among breast cancer survivors: a meta-analysis. *Psychooncology*. 2019; 28(2):255–263.

24. Shedden-Mora MC, Pan Y, Heisig SR, et al. Optimizing expectations about endocrine treatment for breast cancer: results of the randomized controlled psy-breast trial. *Clin Psychol Eur*. 2020; 2(1):1–20.

25. Collins LM, Kugler KC, Gwadz MV. Optimization of multicomponent behavioral and biobehavioral interventions for the prevention and treatment of HIV/AIDS. *AIDS Behav*. 2016; 20(1):197–214.

26. Collins LM. *Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST)*. Cham: Springer International Publishing; 2018.

27. Collins LM. Introduction to the factorial optimization trial. In: *Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST)*. Cham: Springer International Publishing; 2018:67–113.

28. Collins LM, Strayhorn JC, Vanness DJ. One view of the next decade of research on behavioral and biobehavioral approaches to cancer prevention and control: intervention optimization. *Transl Behav Med*. 2021; 11(11):1998–2008.

29. Green SMC, French DP, Graham CD, et al. Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy. *BMC Health Serv Res*. 2022; 22(1):1081.

30. Bingel U; Placebo Competence Team. Avoiding nocebo effects to optimize treatment outcome. *JAMA*. 2014; 312(7):693–694.

31. Webster RK, Weinman J, Rubin GJ. How does the side-effect information in patient information leaflets influence peoples' side-effect expectations? A cross-sectional national survey of 18- to 65-year-olds in England. *Health Expect*. 2017; 20(6):1411–1420.

32. Webster RK, Rubin GJ. Influencing side-effects to medicinal treatments: a systematic review of brief psychological interventions. *Front Psychiatry*. 2019; 9:775.

33. Von Blanckenburg P, Schuricht F, Albert U-S, Rief W, Nestoriuc Y. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. *BMC Cancer*. 2013; 13(1):426.

34. Jacob Arriola KR, Mason TA, Bannon KA, et al. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. *Patient Educ Couns*. 2014; 95(1):98–103.

35. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor—positive breast cancer. *J Clin Oncol*. 2004; 22(16):3309–3315.

36. Rottman BM, Marcum ZA, Thorpe CT, Gellad WF. Medication adherence as a learning process: insights from cognitive psychology. *Health Psychol Rev*. 2017; 11(1):17–32.

37. Kincaid JP, Fishburne Jr RP, Rogers RL, Chissom BS. *Derivation of New Readability Formulas (Automated Readability Index, Fog Count and Flesch Reading Ease Formula) for Navy Enlisted Personnel*. Naval Technical Training Command Millington TN Research Branch. Memphis, TN: U. S. Naval Air Station; 1975.

38. Collins LM, Collins LM. Gathering information for decision-making in the optimization phase: resource management and practical issues. In: *Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST)*. Cham: Springer International Publishing; 2018:193–225.

39. Jones ASK, Petrie KJ. I can see clearly now: using active visualisation to improve adherence to ART and PrEP. *AIDS Behav*. 2017; 21(2):335–340.

40. Karamanidou C, Weinman J, Horne R. Improving haemodialysis patients' understanding of phosphate-binding medication: a pilot study of a psycho-educational intervention designed to change patients' perceptions of the problem and treatment. *Br J Health Psychol*. 2008; 13(2):205–214.

41. Perera AI, Thomas MG, Moore JO, Faasse K, Petrie KJ. Effect of a smartphone application incorporating personalized health-related imagery on adherence to antiretroviral therapy: a randomized clinical trial. *AIDS Patient Care STDS*. 2014; 28(11):579–586.

42. Garcia-Retamero R, Cokely ET. Designing visual aids that promote risk literacy: a systematic review of health research and evidence-based design heuristics. *Hum Factors*. 2017; 59(4):582–627.

43. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. *JAMA*. 2002; 287(5):622–627.

44. Nestoriuc Y, Von Blanckenburg P, Schuricht F, et al. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. *Ann Oncol*. 2016; 27(10):1909–1915.

45. Webster RK, Weinman J, Rubin GJ. A systematic review of factors that contribute to nocebo effects. *Health Psychol*. 2016; 35(12):1334–1355.

46. Smith LE, Webster RK, Rubin GJ. A systematic review of factors associated with side-effect expectations from medical interventions. *Health Expect*. 2020; 23(4):731–758.

47. Webster RK, Weinman J, Rubin GJ. Positively framed risk information in patient information leaflets reduces side effect reporting: a double-blind randomized controlled trial. *Ann Behav Med*. 2018; 52(11):920–929.

48. Michnevich T, Pan Y, Hendi A, Oechsle K, Stein A, Nestoriuc Y. Preventing adverse events of chemotherapy for gastrointestinal cancer by educating patients about the nocebo effect: a randomized-controlled trial. *BMC Cancer*. 2022; 22(1):1008.

49. Kim HS, Bigman CA, Leader AE, Lerman C, Cappella JN. Narrative health communication and behavior change: the influence of exemplars in the news on intention to quit smoking. *J Commun*. 2012; 62(3):473–492.

50. Brett J, Hulbert-Williams NJ, Fenlon D, et al. Psychometric properties of the Beliefs about Medicine Questionnaire-adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer. *Health Psychol Open*. 2017; 4(2):2055102917740469.

51. Collins LM, Huang L, Dziak J. *MOST: Multiphase Optimization Strategy, R package version 0.1.2*. 2022. https://cran.r-project.org/web/packages/MOST/MOST.pdf

52. Collins LM. The completion of the optimization phase. In: *Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST)*. Cham: Springer International Publishing; 2018:227–266.

53. Kuhn J, Sheldrick RC, Broder-Fingert S, et al. Simulation and minimization: technical advances for factorial experiments designed to optimize clinical interventions. *BMC Med Res Methodol*. 2019; 19(1):1–9.

54. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2022.

55. Collins LM. Interactions between components and moderation of component effects. In: *Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization*

Strategy (MOST). Cham: Springer International Publishing; 2018:115–143.

56. Foot H, La Caze A, Gujral G, Cottrell N. The necessity–concerns framework predicts adherence to medication in multiple illness conditions: a meta-analysis. *Patient Educ Couns*. 2016; 99(5):706–717.

57. Arigo D, Suls JM, Smyth JM. Social comparisons and chronic illness: research synthesis and clinical implications. *Health Psychol Rev*. 2014; 8(2):154–214.

58. Festinger L. A theory of social comparison processes. *Hum Relat*. 1954; 7(2):117–140.

59. Reyna VF. A theory of medical decision making and health: fuzzy trace theory. *Med Decis Making*. 2008; 28(6):850–865.

60. Reyna VF, Edelson S, Hayes B, Garavito D. Supporting health and medical decision making: findings and insights from fuzzy-trace theory. *Med Decis Making*. 2022; 42(6):741–754.

61. Jones ASK, Ellis CJ, Nash M, Stanfield B, Broadbent E. Using animation to improve recovery from acute coronary syndrome: a randomized trial. *Ann Behav Med*. 2016; 50(1):108–118.

62. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. *Patient Educ Couns*. 2005; 59(1):97–102.

63. Strayhorn JC, Collins LM, Brick TR, et al. Using factorial mediation analysis to better understand the effects of interventions. *Transl Behav Med*. 2022; 12(1):137.